Avexitide: a GLP-1 Blocker Cuts Hypoglycaemia by 55%

Almost everything written about GLP-1 in the past three years concerns activating the receptor. On 18 August 2026, Amylyx Pharmaceuticals announced positive topline results for a compound that does the opposite.

Avexitide is described by the company as an investigational, first-in-class GLP-1 receptor antagonist. It blocks the receptor that semaglutide, tirzepatide and retatrutide are designed to switch on. According to Amylyx, the phase 3 LUCIDITY trial met its primary endpoint with a 55 percent reduction in hypoglycaemic events compared with placebo.

Everything below comes from the company announcement. This is a topline press release, not a peer-reviewed publication, and the distinction matters throughout. Avexitide is investigational, is not approved anywhere, and is not in the Peptra Labs catalogue.

Why blocking the receptor is the point

The condition is post-bariatric hypoglycaemia, which occurs in some people after Roux-en-Y gastric bypass surgery.

Amylyx describes the mechanism plainly: in this condition an exaggerated GLP-1 response leads to excessive insulin secretion, which produces recurrent hypoglycaemic events. Too much insulin at the wrong moment, driven by too much GLP-1 signalling.

If that is the problem, then the entire logic of the drug class inverts. Avexitide is described as a competitive GLP-1 receptor antagonist designed to bind the GLP-1 receptor on pancreatic islet beta cells and inhibit the exaggerated response.

That is a useful reminder that a receptor is not inherently good or bad to stimulate. It depends entirely on what has gone wrong upstream.

What the avexitide trial did

LUCIDITY enrolled 78 adult participants with post-bariatric hypoglycaemia following gastric bypass surgery. It was a multicentre, randomised, double-blind, placebo-controlled trial.

Participants were randomised 3 to 2 to receive either 90 mg avexitide subcutaneously once daily, or placebo. The double-blind period ran 16 weeks. A 32-week open-label extension remains ongoing, according to the company.

The endpoint definitions come from standard hypoglycaemia grading. Level 2 denotes a blood glucose value low enough to require action, and Level 3 a severe event involving altered mental or physical function that requires assistance from another person. Counting both together, as the primary endpoint does, mixes a measurable threshold with a clinically defined emergency.

The results Amylyx reports

The primary endpoint, which the company says was agreed with FDA, was the composite rate of Level 2 and Level 3 hypoglycaemic events. Amylyx reports a 55 percent reduction compared with placebo through week 16, with a p value of 0.000003.

The company reports that all secondary endpoints were met, with reductions in Level 2 events measured by self-monitoring of blood glucose, Level 2 events measured by continuous glucose monitoring, and independently adjudicated Level 3 events.

On tolerability, Amylyx states that most adverse events were mild to moderate, that there were no serious adverse events related to avexitide, and that the most common adverse events were diarrhoea, injection site erythema and injection site bruising.

The detail that will get missed

One sentence in the release deserves more attention than the headline percentage.

Amylyx reports no changes in body weight in either the avexitide or the placebo group over the 16-week double-blind period.

For a compound acting at the GLP-1 receptor, that is worth sitting with. Receptor agonists in this class produce substantial weight loss, and much of the debate about them concerns how much of their benefit runs through that weight change. Here the receptor is blocked rather than activated, the glycaemic endpoint moves substantially, and body weight does not move at all.

It is a clean illustration that GLP-1 receptor pharmacology and weight change are separable, in at least one direction.

What the announcement is not

Three limits, none of them criticisms of the work.

It is a press release. The company states it plans to present the LUCIDITY data at an upcoming medical meeting. Until then, there is no methods section, no participant characteristics table, and no independent peer review. Topline announcements report what the sponsor chooses to report.

It is 78 participants over 16 weeks. That is an appropriate size for a rare condition and a small evidence base in absolute terms. The p value of 0.000003 describes how unlikely the observed difference is under the null hypothesis. It does not describe how many people were studied, or for how long.

Regulatory designations are not approvals. Amylyx notes Breakthrough Therapy Designation for this indication and Orphan Drug Designation for hyperinsulinemic hypoglycaemia. Those are procedural statuses that affect how FDA engages with a programme. The company says it plans to submit a New Drug Application by the end of 2026.

Why an antagonist matters for peptide research

The interesting part for anyone working with these molecules is the design space.

The GLP-1 field has been dominated by one question: how to activate the receptor harder, longer, and alongside more co-targets. The nine compounds in a recent analytical method paper, where one validated method now identifies nine of them, are all agonists, spanning single, dual and triple receptor designs.

An antagonist such as avexitide, built on the same receptor, points at a different question: what happens when incretin signalling is excessive rather than deficient. Post-bariatric hypoglycaemia is the clearest example, and congenital hyperinsulinism, which Amylyx says avexitide has also been studied in, is another.

It also complicates the picture emerging from agonist trials. We reported a prespecified analysis of inflammation in SELECT in which the anti-inflammatory effect appeared before weight loss. If activating the receptor has effects beyond weight, blocking it presumably does too, and those have not been characterised.

For a broader view of where the published evidence actually sits per compound, our ranking of the most-studied research peptides tracks the literature rather than the announcements.

References

• Amylyx Pharmaceuticals. Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia, 18 August 2026
• Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder. Archives of Endocrinology and Metabolism, 30 March 2023
• Beyond diabetes remission a step further: Post bariatric surgery hypoglycemia. World Journal of Diabetes, 15 March 2022

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.